Proliposomal testosterone formulations
Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.
1. A proliposomal powder dispersion, consisting essentially of
(a) native testosterone,
(b) cholesterol, and
(c) at least one phospholipid,
wherein (a) and (b) are present in a weight ratio (a):(b) ranging from 1.0:0.05 to 1.0:0.30 and (a), (b) and (c) are present in a weight ratio of (a):((b)+(c)) ranging from 1.0:1.0 and 1.0:2.5.
2. A proliposomal powder dispersion of claim 1 , wherein the phospholipid is selected from distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, dimyrsityl phosphatidyl glycerol sodium, 1,2-dimyristoyl-phosphatidic acid, dipalmitoylphosphatidylglycerol, dipalmitoyl phosphate, 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol, 1,2-distearoyl-sn-glycero-3-phosphatidic acid, phosphatidylserine and sphingomyelin, or a combination thereof.
3. A proliposomal powder dispersion of claim 2 wherein the phospholipid is distearoyl phosphatidylcholine.
4. A pharmaceutical composition comprising a proliposomal powder dispersion of claim 1 and at least one pharmaceutically acceptable excipient.
5. An oral dosage form comprising the pharmaceutical composition of claim 4 , wherein the oral dosage form is a tablet or capsule, and wherein the tablet or capsule is coated with a delayed release coating.
6. An oral dosage form comprising the pharmaceutical compositions of claim 4 , wherein the oral dosage form is a tablet or capsule, and wherein the tablet or capsule is coated with an enteric coating.
7. An oral dosage form, comprising
a proliposomal powder dispersion of claim 1 and
at least one pharmaceutically acceptable excipient,
wherein the native testosterone is present in an amount ranging from 50 to 260 mg and having a fasting pharmacokinetic profile of a mean plasma concentration of testosterone ranging from 300 to 950 ng/dL of testosterone at five hours after ingestion.
8. An oral dosage form of claim 7 , wherein the oral dosage form is a capsule, and wherein the capsule is coated with a delayed release coating.
9. A method of treating an individual in need of testosterone therapy, comprising administering a therapeutically effective amount of the proliposomal powder dispersion of claim 1 to the individual.
10. A method of treating an individual in need of testosterone therapy, comprising administering a therapeutically effective amount of the oral dosage form of claim 7 to the individual.
11. A proliposomal powder dispersion of claim 1 , wherein:
the phospholipid is selected from distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, dimyrsityl phosphatidyl glycerol sodium, 1,2-dimyristoyl-phosphatidic acid, dipalmitoylphosphatidylglycerol, dipalmitoyl phosphate, 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol, 1,2-distearoyl-sn-glycero-3-phosphatidic acid, phosphatidylserine and sphingomyelin, or a combination thereof;
(a) and (b) are present in a weight ratio (a):(b) ranging from 1.0:0.08 to 1.0:to 0.12; and
(a), (b) and (c) are present in a weight ratio of (a):((b)+(c)) ranging from 1.0:1.0 to 1.0:1.2.
12. A proliposomal powder dispersion of claim 11 wherein the phospholipid is distearoyl phosphatidylcholine.
13. A pharmaceutical composition comprising a proliposomal powder dispersion of claim 11 and at least one pharmaceutically acceptable excipient.
14. A pharmaceutical composition comprising a proliposomal powder dispersion of claim 12 and at least one pharmaceutically acceptable excipient.
15. A method of treating an individual in need of testosterone therapy comprising administering to said individual a therapeutically effective amount of the proliposomal powder dispersion of claim 11 .
16. A proliposomal powder dispersion of claim 1 , wherein the dispersion is admixed with microcrystalline cellulose, and
wherein the dispersion and the microcrystalline cellulose are present in a weight ratio ranging from about 1:0.5 to about 1:2.
17. An oral dosage form of claim 7 , wherein the dispersion is admixed with microcrystalline cellulose, and
wherein the dispersion and the microcrystalline cellulose are present in a weight ratio ranging from about 1:0.5 to about 1:2.
18. A proliposomal powder dispersion according to claim 16 , wherein the dispersion and the microcrystalline cellulose are present in a weight ratio ranging from about 1:0.5 to about 1:1.
19. An oral dosage form according to claim 17 , wherein the dispersion and the microcrystalline cellulose are present in a weight ratio ranging from about 1:0.5 to about 1:1, and wherein the native testosterone is present in an amount ranging from 50 to 260 mg and having a fasting pharmacokinetic profile of a mean plasma concentration of testosterone ranging from 300 to 950 ng/dL of testosterone at five hours after ingestion.
20. An oral dosage form of claim 7 , having a fasting pharmacokinetic profile of a mean plasma concentration of testosterone ranging from 350 to 950 ng/dL of testosterone at five hours after ingestion.